Zachary A. Marcum

Zachary A. Marcum

Auto-generated profile, based on publicly available information

Zachary A. Marcum

Department of Pharmacy, University of Washington School of Pharmacy, Seattle

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2016 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
ZMZachary A. Marcum
Zachary A. Marcum
SPSubashan Perera
Subashan Perera
JTJoshua M. Thorpe
Joshua M. Thorpe
GSGalen E. Switzer
Galen E. Switzer
NCNicholas G. Castle
Nicholas G. Castle
HSHealth ABC Study
Health ABC Study
Background: Few studies have compared the risk of recurrent falls across various antidepressant agents—using detailed dosage and duration data—among community-dwelling older adults, including those who have a history of a fall/fracture. Objective: To examine the association of antidepressant use with recurrent falls, including among those with a history of falls/fractures, in community-dwelling elders. Methods: This was a longitudinal analysis of 2948 participants with data collected via interview at year 1 from the Health, Aging and Body Composition study and followed through year 7 (1997-2004). Any antidepressant medication use was self-reported at years 1, 2, 3, 5, and 6 and further categorized as (1) selective serotonin reuptake inhibitors (SSRIs), (2) tricyclic antidepressants, and (3) others. Dosage and duration were examined. The outcome was recurrent falls (≥2) in the ensuing 12-month period following each medication data collection. Results: Using multivariable generalized estimating equations models, we observed a 48% greater likelihood of recurrent falls in antidepressant users compared with nonusers (adjusted odds ratio [AOR] = 1.48; 95% CI = 1.12-1.96). Increased likelihood was also found among those taking SSRIs (AOR = 1.62; 95% CI = 1.15-2.28), with short duration of use (AOR = 1.47; 95% CI = 1.04-2.00), and taking moderate dosages (AOR = 1.59; 95% CI = 1.15-2.18), all compared with no antidepressant use. Stratified analysis revealed an increased likelihood among users with a baseline history of falls/fractures compared with nonusers (AOR = 1.83; 95% CI = 1.28-2.63). Conclusion: Antidepressant use overall, SSRI use, short duration of use, and moderate dosage were associated with recurrent falls. Those with a history of falls/fractures also had an increased likelihood of recurrent falls.

14 October 2019 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
DBDeborah E. Barnes
Deborah E. Barnes
JZJing Zhou
Jing Zhou
RWRod L. Walker
Rod L. Walker
ELEric B. Larson
Eric B. Larson
SLSei J. Lee
Sei J. Lee
SDSascha Dublin
Sascha Dublin

17 February 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
LHLaura A. Hart
Laura A. Hart
EPElizabeth A. Phelan
Elizabeth A. Phelan
JYJulia Y. Yi
Julia Y. Yi
ZMZachary A. Marcum
Zachary A. Marcum
SGShelly L. Gray
Shelly L. Gray

11 September 2019 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
PGParag Goyal
Parag Goyal
TATimothy S. Anderson
Timothy S. Anderson
GBGwen M. Bernacki
Gwen M. Bernacki
ZMZachary A. Marcum
Zachary A. Marcum
AOAriela R. Orkaby
Ariela R. Orkaby
MRMichael W. Rich
Michael W. Rich
BACKGROUND/OBJECTIVES: Guideline‐based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties. DESIGN: National cross‐sectional survey. SETTING: Ambulatory. PARTICIPANTS: Random sample of geriatricians, general internists, and cardiologists from the American College of Physicians. MEASUREMENTS: Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases. RESULTS: In each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P < .001), such as recurrent metastatic cancer (84% of geriatricians, 68% of general internists, and 45% of cardiologists), Alzheimer dementia (92% of geriatricians, 81% of general internists, and 59% of cardiologists), or significant functional impairment (83% of geriatricians, 68% of general internists, and 45% of cardiologists). CONCLUSIONS: While barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician‐physician and physician‐patient communication. J Am Geriatr Soc 68:78–86, 2019

20 July 2021 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
ZMZachary A. Marcum
Zachary A. Marcum
SJShangqing Jiang
Shangqing Jiang
JBJennifer L. Bacci
Jennifer L. Bacci
TRTodd M. Ruppar
Todd M. Ruppar

2 April 2018 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MSManvi Sharma
Manvi Sharma
AVAisha Vadhariya
Aisha Vadhariya
MJMichael L. Johnson
Michael L. Johnson
ZMZachary A. Marcum
Zachary A. Marcum
HHHolly M. Holmes
Holly M. Holmes
While many new medications may offer advantages over existing drugs, some newer drugs are reformulations of existing products that provide little innovation or incremental benefit while driving up drug costs. Despite the lack of benefit of these medications, prescribers may be motivated by payments made by the pharmaceutical industry. The objective of the study was to determine the association between payments made to physicians by the pharmaceutical industry and prescriptions for certain selected costly brand name drugs. This was a cross-sectional, retrospective study linking the Open Payments Database and Medicare Part D Prescriber Public Use File for 2014, including 667,278 physicians who prescribed one of 6 brand-name drugs with less costly but similarly effective alternatives: lovastatin ER, almotriptan, amlodipine+olmesartan, ibuprofen+famotidine, saxagliptin+metformin and naproxen+esomeprazole. The primary outcome was the odds of a physician prescribing one of the selected drugs, and the primary predictor was the receipt of any payment from the pharmaceutical industry. The odds of prescribing 3 of the 6 drugs were increased among physicians who received industry payment, compared to those without payment: amlodipine+olmesartan, aOR 1.42, (95% CI 1.36–1.49); saxagliptin+metformin, aOR 1.50, (95% CI 1.42–1.59); and naproxen+esomeprazole, aOR 1.45, (95% CI 1.25–1.68). Payment from the manufacturer of the specific drug, compared to not receiving payment from the drug’s manufacturer, was associated with increased odds of prescribing 4 of the 6 drugs: amlodipine+olmesartan, aOR 2.40, (95% CI 2.29–2.52), ibuprofen+famotidine, aOR 8.06, (95% CI 5.42–12.00), saxagliptin+metformin, aOR 2.21, (95% CI 2.10–2.34) and naproxen+esomeprazole, aOR 5.96, (95% CI 5.08–7.00). A physician-industry financial relationship was associated with increased odds of prescribing costly brand-name drugs of uncertain medical benefit. Patients, as healthcare consumers, should demand transparency from their physicians about payment from the pharmaceutical industry to increase shared decision-making. Physician and policy makers need increased awareness and reflection on how industry payment influences their prescribing practices.